Background. Paracetamol overdose can cause acute kidney injury (AKI) independent of its hepatotoxic effects. We aimed to determine the prevalence of AKI (AKI Network definition) in those with paracetamol-induced hepatotoxicity, identify factors associated with development, assess impact on the outcomes of patient survival and length of stay and determine the proportion of patients recovering renal function (estimated glomerular filtration rate > 60 mL/min) by the time of hospital discharge or transfer out. Methods. Between 2000 and 2007, patients admitted to a tertiary referral liver intensive therapy unit (LITU) with paracetamol-induced hepatotoxicity were identified from a prospectively maintained database and evaluated. Results. Those receiving a liver transplant were excluded (n ¼ 54), leaving 302 patients. Renal function remained normal in 21%, the remainder developing AKI (Stages 1-8%, 2-6% and 3-65%). Vasopressor requirement, mechanical ventilation, higher admission phosphate and lower sodium levels along with a higher Day 3 lactate and lower haematocrit were associated with AKI. In survivors with AKI, 51% had recovery of renal function, while 7% remained dialysis dependant although none required it chronically. Overall, there was 25% mortality, all having Stage 3 AKI but AKI was only a univariate not multivariate predictor of reduced patient survival. AKI independently predicted longer length of stay. Conclusions. AKI is very common in critically ill patients with paracetamol-induced hepatotoxicity requiring LITU admission. Although outcomes are poorer with AKI than with normal renal function, they are better than those found in other intensive therapy unit populations. Gradual recovery of renal function is seen in all patients.
Introduction
Acute kidney injury (AKI) occurs in 40-80% of patients with acute liver failure (ALF) [1, 2] . The underlying aetiology is frequently multifactorial and AKI may occur as a consequence of sepsis, hypovolaemia-induced renal hypoperfusion, hepatorenal syndrome, intra-abdominal hypertension or there may be a common underlying cause for the hepatic and renal toxicity including drugs, such as paracetamol [3, 4] .
Paracetamol is a commonly used analgesic and paracetamol-induced hepatotoxicity remains the most common aetiology of ALF in the UK and USA [5, 6] . Hepatotoxicity, defined as an aspartate aminotransferase level of >1000 IU/L, following intentional or unintentional ingestion of paracetamol is observed in 3-26% of patients, depending on the factors including time to presentation for treatment with N-acetylcysteine [7, 8] . ALF (hepatotoxicity in the presence of encephalopathy and coagulopathy), however, is relatively rare.
Acute renal impairment occurs in 2-10% of patients who ingest excessive amounts of paracetamol. It has also been noted in the absence of hepatotoxicity [9] [10] [11] [12] . Although renal biopsy is rarely undertaken in patients with AKI, a pattern of acute tubular injury due to toxic metabolites (n-acetyl-p-benzo-quinone-imine) generated by primarily liver-derived cytochrome P450 enzymes has been demonstrated [13, 14] . Possible mechanisms are endoplasmic reticulum injury and caspase-dependent induction of apoptosis, with Bcl-xL being identified as a potential therapeutic target to prevent paracetamol-induced tubular cell death [15, 16] . N-acetylcysteine can ameliorate both the liver and renal damage, if given within an appropriate time frame post-ingestion [17] .
Until recently, clinical information relating to AKI postparacetamol ingestion came primarily from small studies and case series [18] [19] [20] [21] . A larger study, albeit in 1977, looking at 160 patients with fulminant hepatic failure, demonstrated that the rate of acute renal failure in those with paracetamol-induced ALF was higher than that seen with other aetiologies of ALF (53 versus 38%) [2] . A more recent paper evaluating the role of the systemic inflammatory response syndrome (SIRS) in predicting renal dysfunction in ALF has supported these findings, demonstrating AKI in 80% of patients with paracetamol-induced ALF compared with 51% in those with non-paracetamolinduced ALF [22] . These authors used the RIFLE (Risk, Injury, Failure, Loss, End-stage kidney disease) criteria to define renal injury [23] . This definition has since been updated by the AKI Network [24] .
We aimed to examine the prevalence of all stages of AKI in patients admitted to a liver intensive therapy unit (LITU) with hepatotoxicity post-paracetamol ingestion using this AKI Network definition. We also aimed to identify factors associated with the development of AKI and to examine recovery of renal function at the time of hospital discharge. Finally, we analysed the impact of all stages of AKI on the patient outcomes of in-hospital survival and length of hospital stay.
Materials and methods

Patients
Patients admitted to a tertiary referral LITU with paracetamol-induced hepatotoxicity were identified from a prospectively compiled LITU database that was updated daily. The time period studied was from January 2000 to December 2007. The criteria for patient transfer to the unit included metabolic acidosis, coagulopathy, renal failure, hypoglycaemia, encephalopathy and thrombocytopaenia [25] . The standard treatment protocols used have been described previously [25] . Those <16 years of age and patients, who subsequently received a liver transplant during the course of their treatment, were excluded. As this was a retrospective review and all results were anonymous, the Ethics Committee at King's College Hospital (KCH) did not deem informed consent to be necessary.
Assessment of AKI and renal recovery
Renal function was assessed daily and patients were categorized using the AKI Network serum creatinine criteria [24] . All patients who required renal replacement therapy were classed as Stage 3. While in the LITU, continuous venovenous haemofiltration was provided and once discharged to the ward, they received intermittent haemodialysis. Patients were stratified according to the highest AKI stage attained during their hospital stay and the prevalence of each stage was determined. Length of time on renal replacement therapy was assessed. In those that survived, renal function was evaluated at the time of hospital discharge to home or another hospital by examining the urine output, last available creatinine and any ongoing renal replacement therapy requirements. The estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease equation [26] . As the baseline creatinine was not available in the majority of cases, complete recovery of renal function was defined as an eGFR > 60 mL/min at hospital discharge [23, 27] . Where patients failed to recover renal function upon transfer back to their local units, then these hospitals were contacted to obtain a follow-up eGFR at 3 months or earlier, where the former was unavailable.
Demographic, clinical and laboratory variables
To identify factors and outcomes associated with the development of AKI, demographic, clinical and laboratory information was retrospectively obtained from prospectively maintained LITU, renal unit and laboratory databases and from detailed discharge summaries.
Variables assessed included age, gender, race and any previous medical history of diabetes, hypertension, chronic kidney disease, harmful alcohol consumption or dependence, time to initial presentation for medical treatment, whether the paracetamol was taken at one time point or was staggered over hours to days, the total dose taken, the paracetamol level at presentation, details of other drugs ingested and time to N-acetylcysteine treatment [28] [29] [30] [31] .
The overall severity of illness was determined by the Acute Physiology and Chronic Health Evaluation (APACHE) II score within 24 h of admission, using standard variables [32] . The Sequential Organ Failure Assessment (SOFA) score was calculated to assess the extent of organ dysfunction and scores from the day of admission and Day 3 were analysed. This score is based on the following: arterial partial pressure of oxygen/fraction of inspired oxygen, platelet count, serum bilirubin, mean arterial pressure or vasopressor requirements, Glasgow Coma Scale, serum creatinine or urine output [33] . Each aspect of this score was assessed independently in addition to evaluating the overall score.
Along with bilirubin, the degree of liver dysfunction was evaluated by assessing serum albumin, aspartate transaminase and international normalized ratio on admission and Day 3. The arterial lactate and ammonia and serum phosphate at both of these time points was also recorded [34] . The development of hypoglycaemia (<3 mmol/L) at any time during the LITU stay was documented along with occurrence and grade of encephalopathy and the development of raised intracranial pressure [35] . The need for ventilation at any point throughout the LITU stay was documented. Sepsis was noted and defined as the presence of a combination of microbiologically or radiologically proven infection and at least two SIRS components (temperature over 38°C or <36°C, heart rate >90 beats/min, white cell count over 12 3 10 9 /L or <4 3 10 9 /L) [36, 37] . Patients meeting the KCH criteria (pH < 7.3 or the combination of a creatinine >300 lmol/L, an international normalized ratio >6.5 and Grade III/IV encephalopathy) for liver transplantation during their LITU stay were identified [38] . The Model for End-Stage Liver disease (MELD) score was calculated on the day of admission and Day 3 using the following formula 3.8 3 log e bilirubin (mg/L) 1 11.2 3 log e INR 1 9.57 3 log e creatinine (mg/dL) 1 6.4 [39] . Finally, in-hospital patient survival along with the length of LITU and hospital stay were assessed.
Statistical analysis
Data are expressed as medians and interquartile ranges for continuous data or numbers of patients and percentages for categorical data. Ordinal logistic regression analysis was performed to identify variables associated with development of all stages of AKI (ordinal model). Binary logistic and Cox regression were used to evaluate factors associated with failure to recover renal function by the time of hospital discharge and in-hospital patient survival, respectively. Cox regression analysis was also utilized in the identification of variables influencing death censored and length of hospital stay. In all cases, factors that were found to be significant (P < 0.05) by univariate analysis were selected for multivariate analysis. This is with the exception of the evaluation of factors associated with the development of AKI. In that case, fulfilment of the KCH criteria, overall APACHE II, SOFA and MELD scores were not included in the multivariate analysis. The constituent variables were used instead with the omission of renal variables such as urea, creatinine and urine output. A series of multivariate models were constructed to evaluate the demographic admission and Day 3 clinical and laboratory variables, with the aim of identifying independently significant variables for the final multivariate models. Multicollinearity and model fit were assessed using the correlation matrix and the goodness-of-fit test, respectively. Odds ratios (ORs), hazard ratios (HRs) and their 95% confidence intervals (95% CIs) are reported. SPSS (version 14.0) was used for statistical analysis.
Results
Patients
In the time period studied, 302 patients were admitted to the LITU with paracetamol-induced hepatotoxicity. An additional 54 patients were excluded because they subsequently received a liver transplantation. The majority of patients (59%) were female, 96% were transferred in from other hospitals, the median age was 37 (27-46) years and 91% (n ¼ 274) were Caucasian.
Prevalence and treatment of AKI
The majority developed AKI at some point during their LITU stay, with only 21% (n ¼ 63) preserving renal function. Eight percent (n ¼ 25) developed Stage 1, 6% (n ¼ 19) Stage 2 and the remaining 65% (n ¼ 195) Stage 3 AKI. Of those with Stage 3 AKI, renal replacement therapy was required in 93% (n ¼ 182) for a median of 8 (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) days. Maximal renal injury occurred on Day 2 (1-3).
Ninety percent (n ¼ 164) of the patients requiring continuous renal replacement therapy recovered renal function by the time of discharge from the LITU. Intermittent haemodialysis alone was required in 2% (n ¼ 4); these individuals were discharged from LITU after an average of 3 days, as they had otherwise improved clinically. Both modalities were used sequentially in 8% (n ¼ 14).
Variables associated with development of AKI
Thirty-five different demographic, clinical physiological and laboratory variables were assessed for an association with the development of AKI. Data on time to presentation, dose and level of paracetamol were reliant on the quality of the patient transfer letter, so there was incomplete data in this respect in 37% (n ¼ 112) of patients. Details on the variables significantly linked to development of AKI by univariate ordinal logistic regression are illustrated in Table 1 and those independently associated are shown in Table 2 . It should be noted that Grade III/IV encephalopathy was not significant when included in this model but encephalopathy did closely correlate with the need for ventilation (correlation coefficient of >0.6).
Renal recovery
Of the 239 patients with AKI, 164 patients survived. Of these, 51% (n ¼ 83) had complete recovery of renal function (eGFR > 60 mL/min), while 7% (n ¼ 12) remained dialysis dependent at the time of discharge or transfer to their local units. The median time from LITU discharge to transfer was 5 (0-9) days and those who had incomplete recovery of renal function had a shorter length of hospital stay (OR ¼ 0.65, P ¼ 0.001). Subsequent renal biochemistry from the local hospital or general practitioner was available on 75% (n ¼ 9) of these dialysis-dependent individuals. None went on to require long-term dialysis and the median creatinine and eGFR had improved by 303 (221-453) lmol/L and 20 (17-53) mL/min, respectively, at a median of 38 (19-177) days of follow-up. There was a complete recovery to an eGFR >60 mL/min in all of those followed for at least 3 months (n ¼ 5). Variables independently associated with a failure to recover renal function are illustrated in Table 3 . The other renal variables were also significant if entered into the multivariate model in turn, instead of AKI.
In-hospital patient survival
During their acute admission, 74 patients died resulting in a mortality rate of 25% overall. All the patients who died had Stage 3 AKI giving a mortality rate of 38% in that group. The significant effect of Stage 3 AKI on survival, by univariate analysis, is illustrated in Figure 1 . The median time to death was 9 (3-14) days. Seventy percent (n ¼ 52) of non-survivors met the KCH criteria and the remainder (n ¼ 22) met two of the three criteria for liver transplantation. Of those that met the criteria, 27% (n ¼ 14) were listed for transplantation, the remainder having contraindications to listing. These 14 patients did not receive a liver graft due to clinical deterioration before an organ became available. No patient survived who had fulfilled transplant criteria and did not receive a graft. It should be noted that an additional 54 patients were excluded from the study because they went on to receive a liver transplant having fulfilled transplant criteria. Variables that were found to have a significantly negative impact on patient survival were fulfilment of the KCH transplant criteria, history of hypoglycaemia, a higher lactate on admission and a higher MELD score on Day 3. Details are illustrated in Table 4 . No independent association was demonstrated between AKI or any of the other renal variables and reduced patient survival. Renal function is, however, a component of both the MELD score and the KCH paracetamol listing criteria.
Length of hospital stay
The lengths of hospital and LITU stay were significantly longer in those with AKI at 13 (6-23) and 9 (4-17) days (P < 0.001) versus those without at 5 (4-6) and 2 (2-4) days, respectively (P < 0.001). There was a negative relationship between the following variables and earlier hospi- 
Discussion
This is one of the largest cohorts to look at AKI in patients admitted to an LITU with paracetamol-induced hepatotoxicity and the first to examine the prevalence of all stages of AKI using the AKI Network definition and look at renal recovery. Clinical and laboratory factors associated with development of AKI have been described. Half of those with AKI had complete recovery of renal function by the time of hospital discharge to the referring hospital and none required long-term renal replacement therapy. An association was demonstrated between Stage 3 AKI and reduced patient survival and longer length of hospital stay by univariate and multivariate analysis, respectively.
Until 2004, AKI research was hampered by the lack of a consensus definition. Renal impairment, defined by the RIFLE criteria, has since been shown to predict reduced patient survival and has been validated in a number of populations including those with cirrhotic liver failure [40] . This definition was modified in 2007 to account for new information including data that even small increments in creatinine are associated with increased patient mortality [41, 42] .
We have shown that development of AKI was common post-paracetamol-induced hepatotoxicity (79%) with the majority of patients requiring renal replacement therapy. This mirrors findings in previous studies, although definitions of AKI vary. In one multicentre study of 275 patients with paracetamol-induced ALF, the proportion of patients with a creatinine >176.8 lmol/L ranged between 43 and 57% depending on whether the overdose was intentional or not [43] . More recently, in a retrospective study including 217 similar patients, 76% were found to have AKI, defined as at least a doubling in serum creatinine. They also found that paracetamol was an independent risk factor for AKI. The rates of AKI in patients with paracetamol hepatotoxicity are higher than those in other critically ill patients such as trauma victims (18%) and those with and without sepsis (42 and 34%, respectively) [44, 45] . Therefore, it appears that paracetamol has an independent nephrotoxic effect on the kidney and this is supported by the animal work, previously mentioned [15, 16] . Six variables were found to be independently associated with development of AKI including the need for ventilation, which correlated closely with Grade III/IV encephalopathy as these patients need airway protection [25] . Requirement for vasopressor support was also associated. Other authors have found links with similar factors, namely raised intracranial pressure and hypotension [46] . Development of hypophosphataemia negatively correlated with development of AKI in our study. Hyperphosphataemia is common in renal failure and positively correlates with creatinine and poor prognosis in patients with paracetamol-induced hepatotoxicity. Conversely, hypophosphataemia is a manifestation of increased renal tubular loss and hepatic regeneration [47] . Another associated variable was hyponatraemia, possibly dilutional because of oliguria and subsequent fluid accumulation. In addition, it may be due to inappropriate avoidance of saline for resuscitation in ALF. The haematocrit was also significantly reduced at Day 3. The reasons for this are multifactorial in AKI and critically ill patients [48] . Finally, elevated lactate levels on Day 3 were seen in AKI, correlating with data from another study in patients with paracetamolinduced ALF [34] . The kidney is responsible for up to 30% of lactate clearance but lactate levels can also be elevated in ALF, particularly if associated with multiple organ dysfunction, increasing lactate production and reducing hepatic metabolism [34, 49] . Of note, SIRS was not linked with AKI in this study, echoing findings by other authors; however, it is related to the development of AKI in those with non-paracetamol-induced ALF [46] .
In those with AKI that survived, 51% recovered renal function by the time of hospital discharge or transfer to another hospital. There are inconsistent definitions of renal recovery in the literature. Most authors have used dialysis independence at hospital discharge, but the definition used in our study was that proposed in a recent meta-analysis [27] . This was also used in a prospective study evaluating renal recovery in critically ill patients where 32% of patients recovered renal function by the time of hospital discharge, a rate lower than that seen in our study [50] . Dialysis dependency at hospital discharge in general intensive therapy unit (ITU) populations has also been evaluated and found to be between 14 and 32%, considerably higher than the 7% seen in this population where none of the patients required dialysis chronically. The superior recovery rates with paracetamol hepatotoxicity could be attributed to the fact that the general ITU patients tend to be older and more likely to have pre-existing chronic kidney disease and reflect the potentially reversible nature of paracetamolinduced renal injury [51, 52] . There is little information in the literature about renal recovery specifically postparacetamol hepatotoxicity with the exception of case reports or case series [11, 20, 53] . We identified four factors linked to failure to recover renal function including male gender. Males have a greater propensity to develop chronic kidney disease but there is conflicting data on recovery from AKI [54] [55] [56] . A slightly higher mean arterial pressure on Day 1 and a shorter length of hospital stay were also related to delayed renal recovery, perhaps suggesting that these individuals were less systemically unwell and were discharged before the renal function had an opportunity to fully recover. Creatinine is a component of the MELD score so, not unexpectedly, a higher score correlated with a poorer discharge eGFR. Similarly, unsurprising was the fact that those with a higher AKI stage were more likely to have ongoing renal impairment at discharge.
Overall, there was a 25% mortality rate noted in this study. A similar rate of 27% was reported in two US multicentre studies with similar patients [6, 43] . Spontaneous survival rates are considerably better in those with paracetamol-induced ALF compared with alternative aetiologies such as other drugs or indeterminate causes (65 versus 25%) [6, 57] . In our study, all the patients who died had AKI Stage 3 resulting in a mortality rate in this group of 38%. Similar to other authors, we found that AKI Stage 3 was closely related to reduced patient survival by univariate analysis only [43, 58] . However, AKI is an independent predictor of mortality in the wider ALF population [46, 59] . Therefore, unlike many other ITU populations, poor renal function does not seem to be independently sufficient to reduce survival in those with paracetamol-induced hepatotoxicity [44, [60] [61] [62] [63] . Other variables were found to be independently associated with increased mortality included hypoglycaemia, which has previously been noted to be a poor prognostic indicator in ALF [46] . The KCH criteria is the most commonly used and validated method for stratifying patients into prognostic groups and patient selection for liver transplantation. Its diagnostic value has again been demonstrated here [38] . The addition of arterial lactate has been proposed for the early identification of those likely to meet the KCH criteria post-paracetamol-induced ALF. Like others, we demonstrated this link between hyperlactaemia and reduced survival [34, 37] . A higher MELD score has also previously been shown to correlate with poorer outcome [64] . Additional associated variables demonstrated by other authors include hyperphosphataemia and an APACHE II score > 15 [47, 65] .
Development of AKI had a negative impact on length of stay in this study, in keeping with reports in other ITU populations [44, 55] . We identified a relationship between longer length of stay and sepsis, mirroring what is seen in the general ITU population [44] . A higher lactate was also associated, probably reflecting the greater severity of illness in these individuals [34] .
This study has some limitations. Although the databases were maintained prospectively, it is a retrospective study. On the whole, the patients were previously medically well and usually did not have baseline creatinine measurements, impacting on the ability determine the rate of recovery from AKI. Hence, recovery to an eGFR >60 mL/min was used. The use of glomerular filtration rate estimation equations is not ideal in AKI. As many patients were transferred back to their original referring hospital once their clinical condition had improved, information regarding their long-term renal follow-up is incomplete.
In conclusion, using the AKI Network definition, we have shown that all stages of AKI were very common in this LITU cohort of patients with paracetamol-induced hepatotoxicity. This was particularly so for Stage 3 AKI but chronic dialysis dependency didn't occur. Half the patients had complete recovery of renal function by the time of hospital discharge or transfer to another unit. Clinical and laboratory variables associated with the development of AKI have been identified. While AKI was independently associated with prolonged length of hospital stay, it was not an independent predictor of reduced patient survival. Overall, if criteria for liver transplantation are not fulfilled, these patients appear to have a better outcome than other ITU populations given the potentially reversible hepatotoxicity.
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